Details of Disease

General Information of Disease (ID: DISXPIBD)

• Disease Name: Lung squamous cell carcinoma
• Synonyms: squamous cell carcinoma of lung; squamous cell lung cancer; squamous cell lung carcinoma; lung squamous cell carcinoma; epidermoid cell lung carcinoma; squamous cell carcinoma of the lung; epidermoid cell carcinoma of lung; epidermoid cell carcinoma of the lung
• Disease Class: 2C25: Lung cancer
• Definition: A carcinoma arising from squamous bronchial epithelial cells. It may be keratinizing or non-keratinizing. Keratinizing squamous cell carcinoma is characterized by the presence of keratinization, pearl formation, and/or intercellular bridges. Non-keratinizing squamous cell carcinoma is characterized by the absence of keratinization, pearl formation, and intercellular bridges. Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.|In DO this is classified as nscLC, but this leads to logical issues as we have a distinct class for squamous nscLC
• Disease Hierarchy:
  DIS0167R: Metastatic lung cancer
  DISQVIFL: Squamous cell carcinoma
  DISXPIBD: Lung squamous cell carcinoma
• ICD Code: ICD-11: ICD-11: 2C25.2
• Disease Identifiers:
  MONDO ID: MONDO_0005097
  UMLS CUI: C0149782
  MedGen ID: 56202
  HPO ID: HP:0030359
  SNOMED CT ID: 254634000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[1]

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Gilotrifafatinib	DM4JZIM	Phase 2	NA	[2]
CAR-GPC3 T Cells	DMQH2DK	Phase 1	CAR T Cell Therapy	[3]
GPC3 targeting CAR-T cells	DMVWHS1	Phase 1	CAR T Cell Therapy	[4]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 71 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABL2	TT1A6HL	Limited	Biomarker	[5]
CHRNB4	TTTVAFQ	Limited	Genetic Variation	[6]
DBH	TTYIP79	Limited	Genetic Variation	[6]
DDR2	TTU98HG	Limited	Biomarker	[7]
EP300	TTGH73N	Limited	Biomarker	[8]
LCK	TT860QF	Limited	Biomarker	[9]
PKD2L1	TTAHD89	Limited	Genetic Variation	[6]
THRB	TTGER3L	Limited	Genetic Variation	[10]
WNK1	TTJ9UMX	Limited	Genetic Variation	[6]
GPC3	TTJTSX4	Disputed	Altered Expression	[11]
IGF1R	TTQFBMY	Disputed	Biomarker	[12]
CEACAM5	TTY6DTE	moderate	Altered Expression	[13]
EPHB3	TT5LM7U	moderate	Biomarker	[14]
FGFR3	TTST7KB	moderate	Altered Expression	[15]
KRAS	TTM8FR7	moderate	Genetic Variation	[16]
LIPA	TTS8T1M	moderate	Genetic Variation	[17]
NSD1	TTTSJ3H	moderate	Biomarker	[18]
RARB	TTISP28	moderate	Altered Expression	[19]
TMEM97	TT9NXW4	moderate	Altered Expression	[20]
ALK	TTPMQSO	Strong	Genetic Variation	[21]
ALKBH5	TTOHB1M	Strong	Biomarker	[22]
ATXN2	TTPQJ7P	Strong	Genetic Variation	[23]
B2M	TTY7FKA	Strong	Genetic Variation	[24]
BRCA2	TTUARD6	Strong	Genetic Variation	[6]
BRD9	TTR7L5Y	Strong	Biomarker	[25]
CACNA2D3	TTN7T29	Strong	Biomarker	[26]
CEACAM3	TTPX7I5	Strong	Altered Expression	[13]
CHRNA7	TTLA931	Strong	Biomarker	[27]
CREBBP	TTFRCTK	Strong	Genetic Variation	[24]
CSNK2A1	TTER6YH	Strong	Biomarker	[28]
CSNK2A2	TT7GR5W	Strong	Biomarker	[28]
CYP1A2	TTS1DTU	Strong	Genetic Variation	[29]
CYP2A6	TTAQ6ZW	Strong	Genetic Variation	[6]
DCLK1	TTOHTCY	Strong	Genetic Variation	[10]
DSG3	TTEO4P8	Strong	Altered Expression	[30]
EML4	TT92GY4	Strong	Genetic Variation	[31]
EPHA2	TTRJB2G	Strong	Genetic Variation	[32]
FAM83B	TT1Q347	Strong	Altered Expression	[33]
FBXW7	TT29KY7	Strong	Altered Expression	[34]
FGF19	TTGCH11	Strong	Biomarker	[35]
GMNN	TT390KA	Strong	Altered Expression	[36]
GPR87	TTO897C	Strong	Altered Expression	[37]
GRM8	TT0IFKL	Strong	Genetic Variation	[38]
HHAT	TT1VNCG	Strong	Biomarker	[39]
HLA-A	TTHONFT	Strong	Genetic Variation	[6]
HLA-DQA1	TTU2I3J	Strong	Genetic Variation	[6]
KCNH1	TT9XKUC	Strong	Genetic Variation	[23]
KMT5A	TTGC95K	Strong	Biomarker	[40]
LOXL2	TTFSUHX	Strong	Biomarker	[41]
MAPKAP1	TTWDKCL	Strong	Genetic Variation	[42]
NME1	TTDY8JH	Strong	Biomarker	[43]
NOTCH1	TTB1STW	Strong	Biomarker	[44]
PDCD1LG2	TTW14O3	Strong	Altered Expression	[45]
PLK1	TTH4IP0	Strong	Altered Expression	[46]
PRKCI	TTWJTHX	Strong	Biomarker	[47]
PTPN13	TT405FP	Strong	Altered Expression	[48]
SERPINB3	TT6QLPX	Strong	Altered Expression	[49]
SERPINB5	TT1KW50	Strong	Biomarker	[50]
SH2B3	TT36N7Z	Strong	Genetic Variation	[23]
SOX2	TTCNOT6	Strong	Genetic Variation	[51]
SQLE	TTE14XG	Strong	Altered Expression	[52]
SRPK1	TTU3WV6	Strong	Altered Expression	[53]
SRPK2	TTCZEJ9	Strong	Altered Expression	[53]
TACC3	TTQ4UFD	Strong	Biomarker	[54]
TBL1XR1	TTYXT16	Strong	Altered Expression	[55]
TK1	TTP3QRF	Strong	Biomarker	[56]
TOP2A	TTCGY2K	Strong	Biomarker	[57]
TPX2	TT0PHL4	Strong	Biomarker	[58]
VDAC3	TTT48SQ	Strong	Biomarker	[59]
SCGB1A1	TTONPVW	Definitive	Genetic Variation	[60]
STXBP4	TTKS60G	Definitive	Biomarker	[61]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC2A2	DTUJPOL	Strong	Biomarker	[62]

This Disease Is Related to 8 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP1A1	DE6OQ3W	Limited	Genetic Variation	[63]
GPX6	DEOS3FD	Limited	Genetic Variation	[6]
ADHFE1	DE8RJ3F	Strong	Biomarker	[64]
AKR1C2	DEOY5ZM	Strong	Altered Expression	[65]
DIO3	DET89OV	Strong	Biomarker	[66]
GSTM1	DEYZEJA	Strong	Biomarker	[5]
ME1	DE97WM8	Strong	Altered Expression	[67]
THOP1	DE95LJC	Strong	Genetic Variation	[68]

This Disease Is Related to 172 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
APOM	OTI3FQQC	Limited	Genetic Variation	[6]
BTBD9	OTWQ6GA3	Limited	Genetic Variation	[10]
BTN3A3	OTKMSJRA	Limited	Genetic Variation	[6]
CARMIL1	OT1A5IX5	Limited	Genetic Variation	[6]
CENPP	OTXE47T2	Limited	Genetic Variation	[10]
DCUN1D4	OTIEGOZ0	Limited	Genetic Variation	[10]
ESM1	OT331Y8V	Limited	Genetic Variation	[10]
FRY	OT74IAG2	Limited	Genetic Variation	[6]
GAB2	OTBFN705	Limited	Biomarker	[69]
H2AC6	OTF3YK7V	Limited	Genetic Variation	[6]
HCP5	OTV0YRI8	Limited	Genetic Variation	[6]
HLA-DMB	OT17HGXJ	Limited	Genetic Variation	[6]
HLA-DQA2	OT1DH0N9	Limited	Genetic Variation	[6]
KRT81	OTMKIK2S	Limited	Biomarker	[70]
LCORL	OTJNQRC5	Limited	Genetic Variation	[10]
LRRC8D	OTPON2CI	Limited	Genetic Variation	[6]
MMD	OTB5I4OC	Limited	Biomarker	[9]
MORF4L1	OTEA6FYJ	Limited	Genetic Variation	[6]
NEB	OT7P9IR3	Limited	Genetic Variation	[6]
NME2	OTCYGLHV	Limited	Altered Expression	[71]
NPAS3	OT8D1ILB	Limited	Genetic Variation	[6]
PC	OT6O0V51	Limited	Genetic Variation	[10]
PDS5B	OT3U3X8Z	Limited	Genetic Variation	[6]
PGBD1	OTSJX9UU	Limited	Genetic Variation	[6]
PPBP	OT1FHGQS	Limited	Biomarker	[72]
PTPRA	OTZA82J1	Limited	Biomarker	[73]
REXO4	OT2NNFKZ	Limited	Genetic Variation	[6]
SCGN	OTGD7SKH	Limited	Genetic Variation	[6]
TNXB	OTVBWAV5	Limited	Genetic Variation	[6]
TRIM26	OTS0DJIP	Limited	Genetic Variation	[6]
ATG4D	OTSWUO4R	Disputed	Altered Expression	[74]
FAM163A	OT0MYZ0F	Disputed	Biomarker	[75]
MAP1LC3C	OTM4ECDK	Disputed	Altered Expression	[74]
DMRT3	OTNV7F7Q	moderate	Biomarker	[76]
GATA6	OTO2BC0F	moderate	Biomarker	[77]
HNF1B	OTSYIC3T	moderate	Biomarker	[64]
HOPX	OTBSR6C9	moderate	Biomarker	[78]
MASP1	OTWWCNZP	moderate	Biomarker	[14]
MEOX1	OTJEMT2D	moderate	Altered Expression	[79]
SIAH2	OTKED2XN	moderate	Altered Expression	[80]
AP2M1	OTQCOSFN	Strong	Biomarker	[81]
AQP5	OT77GBY8	Strong	Biomarker	[82]
ARL4C	OTQ3QNNU	Strong	Altered Expression	[83]
ARPC5	OTFNMMDL	Strong	Biomarker	[84]
BABAM1	OTCFPER6	Strong	Genetic Variation	[23]
BAG4	OTUPX3M2	Strong	Biomarker	[85]
BIRC6	OTCQJAB0	Strong	Altered Expression	[86]
BRF2	OT2C6TH2	Strong	Biomarker	[87]
BRK1	OTTUB5KS	Strong	Biomarker	[88]
CCL4L2	OTDBSXOU	Strong	Biomarker	[89]
CCNB2	OTIEXTDK	Strong	Biomarker	[90]
CD109	OTDADBM4	Strong	Altered Expression	[91]
CEACAM7	OTKFDTZY	Strong	Altered Expression	[13]
CHFR	OTRAD2TT	Strong	Altered Expression	[92]
CHL1	OT6E6E8P	Strong	Altered Expression	[93]
CHRNA3	OTCZQY1U	Strong	Genetic Variation	[6]
CIZ1	OT3UKHPI	Strong	Biomarker	[94]
CLDN11	OTNN6UTL	Strong	Altered Expression	[95]
CLDN12	OTO55YZI	Strong	Altered Expression	[96]
CLDN3	OT71MN9S	Strong	Altered Expression	[97]
CLDN5	OTUX60YO	Strong	Biomarker	[98]
CLPTM1L	OTDJWQXI	Strong	Genetic Variation	[6]
COL17A1	OTID5AH2	Strong	Biomarker	[99]
CORO1C	OTXDF9T3	Strong	Biomarker	[100]
CXCL17	OTRCEVIZ	Strong	Altered Expression	[101]
CYTL1	OTLYUPUY	Strong	Posttranslational Modification	[50]
DENND2D	OTXEFJWM	Strong	Altered Expression	[102]
DMRT1	OT5PU9U1	Strong	Biomarker	[103]
DNAH5	OTC21RUS	Strong	Altered Expression	[104]
DOCK8	OTNQLL21	Strong	Biomarker	[103]
DSC3	OTYG47F8	Strong	Biomarker	[105]
DUSP6	OT4H6RKW	Strong	Genetic Variation	[106]
ECT2	OTQDUCT6	Strong	Genetic Variation	[107]
EEF2	OTZ7SZ39	Strong	Biomarker	[108]
EIF4G1	OT2CF1E6	Strong	Biomarker	[81]
ELAVL2	OT6EJ8MQ	Strong	Altered Expression	[109]
ERVH48-1	OT303JGE	Strong	Biomarker	[110]
ETV4	OT8C98UZ	Strong	Biomarker	[111]
FBXO45	OTD4D2OP	Strong	Biomarker	[112]
FBXO5	OTTR957W	Strong	Altered Expression	[112]
FOXL2	OTFRQUYL	Strong	Altered Expression	[113]
FXR1	OTEMQ1SR	Strong	Biomarker	[114]
GAS7	OT0M5TNY	Strong	Altered Expression	[115]
GOLM1	OTOZSV6O	Strong	Biomarker	[116]
GPHN	OTAKK1SV	Strong	Altered Expression	[117]
GPR78	OT8TKE6F	Strong	Biomarker	[118]
GRAMD4	OT1HXEPM	Strong	Altered Expression	[36]
GSPT1	OT18H1B0	Strong	Genetic Variation	[119]
H3C1	OTGBGOZW	Strong	Genetic Variation	[113]
HBE1	OTJPKMX4	Strong	Biomarker	[120]
HJV	OT4235J2	Strong	Biomarker	[67]
HLTF	OTRX2OSF	Strong	Genetic Variation	[121]
HNRNPU	OTLQN1E2	Strong	Biomarker	[122]
HYAL3	OTG6VUSP	Strong	Genetic Variation	[123]
IFIT2	OTI4EOAR	Strong	Altered Expression	[124]
IHH	OT1DWGXC	Strong	Altered Expression	[125]
IL17C	OTKXIVNQ	Strong	Altered Expression	[126]
IRX1	OT0ZN9EJ	Strong	Biomarker	[127]
KIF5B	OTT34MT8	Strong	Biomarker	[128]
KRT8	OTTM4X11	Strong	Altered Expression	[129]
LGALS8	OT71LJ8T	Strong	Altered Expression	[130]
LMO3	OTR7AJHN	Strong	Biomarker	[50]
MAP1LC3A	OTPMGIU4	Strong	Altered Expression	[131]
MCM5	OTAHLB62	Strong	Biomarker	[132]
MED12	OTQZ4D2X	Strong	Genetic Variation	[24]
METTL14	OT6TPQMH	Strong	Biomarker	[22]
MIA2	OTOGTUTU	Strong	Genetic Variation	[133]
MKS1	OT83W5PB	Strong	Altered Expression	[67]
MORN5	OTC7R3YL	Strong	Genetic Variation	[134]
MRTFA	OTCVXASM	Strong	Biomarker	[135]
MS4A3	OT0CEJOO	Strong	Biomarker	[136]
MTX1	OTLSDNZO	Strong	Genetic Variation	[23]
MYBPH	OTQJBPUR	Strong	Biomarker	[118]
MYH10	OTXN2WXS	Strong	Altered Expression	[137]
MYO10	OTHB78ZQ	Strong	Biomarker	[137]
NAPSA	OT6F8IAL	Strong	Biomarker	[138]
NCS1	OT6JHAWM	Strong	Altered Expression	[139]
ND5	OT45LW1K	Strong	Altered Expression	[140]
NEK10	OTN0JAYL	Strong	Genetic Variation	[23]
NFIX	OT1DPZAE	Strong	Altered Expression	[141]
NFYC	OTZVVEV7	Strong	Genetic Variation	[142]
NOCT	OTVSYP2D	Strong	Biomarker	[143]
PARN	OTTG4PE3	Strong	Biomarker	[143]
PAX7	OTDMQRPO	Strong	Biomarker	[144]
PDIA6	OT8YBR17	Strong	Altered Expression	[145]
PDPN	OTBUV19I	Strong	Altered Expression	[146]
PEG10	OTWD2278	Strong	Biomarker	[39]
PIAS3	OT3TWH9R	Strong	Altered Expression	[147]
PIK3R2	OTZSUQK5	Strong	Biomarker	[148]
PIWIL1	OT7CRGZ3	Strong	Biomarker	[149]
PIWIL4	OTDA9MY0	Strong	Biomarker	[149]
PKP1	OT9HSQ8F	Strong	Biomarker	[150]
PLAA	OTZ7NJGA	Strong	Biomarker	[151]
PLPP4	OTH5EXZC	Strong	Biomarker	[152]
POU3F2	OT30NFOC	Strong	Altered Expression	[153]
POU4F2	OT6SW5H0	Strong	Biomarker	[118]
PPP6C	OTR1STMJ	Strong	Genetic Variation	[24]
PRC1	OTHD0XS0	Strong	Altered Expression	[154]
PRDM5	OTU1GB68	Strong	Biomarker	[155]
PSG2	OT2EIXAI	Strong	Altered Expression	[13]
PTHLH	OTI1JF13	Strong	Altered Expression	[156]
RAD51B	OTCJVRMY	Strong	Genetic Variation	[23]
RAD52	OT0OTDHI	Strong	Altered Expression	[157]
RALY	OT78NNWY	Strong	Genetic Variation	[23]
RFC4	OTWALD2R	Strong	Biomarker	[158]
RGS3	OTYG5OXI	Strong	Altered Expression	[159]
RIOX2	OT2YFPI2	Strong	Genetic Variation	[160]
RPS14	OTB90KV5	Strong	Biomarker	[161]
SFTPB	OTOHS07E	Strong	Genetic Variation	[162]
SIM1	OTYKFPKZ	Strong	Biomarker	[118]
SOCS6	OT2O5ZBK	Strong	Biomarker	[163]
SOX18	OTPUMHWA	Strong	Altered Expression	[164]
SPAG5	OTCLJ56M	Strong	Biomarker	[90]
SPC25	OTCAS0OH	Strong	Biomarker	[165]
SRSF2	OTVDHO6U	Strong	Biomarker	[53]
STPG4	OT5K4UFL	Strong	Biomarker	[46]
TIA1	OTGPN3P8	Strong	Altered Expression	[166]
TIAL1	OTV2KFZH	Strong	Altered Expression	[166]
TOP3A	OT3CKUI9	Strong	Biomarker	[167]
TPD52	OTPKSK43	Strong	Biomarker	[168]
TRA2B	OTZYQW52	Strong	Biomarker	[104]
TRIM15	OTNYAKP6	Strong	Altered Expression	[169]
TRIM58	OT7OIIRH	Strong	Biomarker	[170]
TTF1	OT4K90WD	Strong	Biomarker	[138]
TTN	OT0LZ058	Strong	Genetic Variation	[171]
ADGRF4	OT4PTCTF	Definitive	Genetic Variation	[60]
ANAPC11	OTK2SJXR	Definitive	Altered Expression	[172]
CCAR2	OTLUDG5T	Definitive	Genetic Variation	[173]
COBL	OTTB4VFQ	Definitive	Genetic Variation	[60]
GPX2	OTXI2NTI	Definitive	Altered Expression	[174]
OVOL1	OTFJ62UI	Definitive	Genetic Variation	[60]
RAD18	OTQ9PLNT	Definitive	Genetic Variation	[175]

References

• [1] The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma. Molecules. 2021 Mar 5;26(5):1392.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT02876978) Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
• [4] ClinicalTrials.gov (NCT03198546) GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
• [5] Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data.Pharmacogenet Genomics. 2015 Jan;25(1):1-7. doi: 10.1097/FPC.0000000000000097.
• [6] Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.Nat Genet. 2017 Jul;49(7):1126-1132. doi: 10.1038/ng.3892. Epub 2017 Jun 12.
• [7] Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.Eur J Med Chem. 2019 Feb 1;163:671-689. doi: 10.1016/j.ejmech.2018.12.015. Epub 2018 Dec 7.
• [8] Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.Mol Cell Proteomics. 2017 Oct;16(10):1864-1888. doi: 10.1074/mcp.M116.064451. Epub 2017 Aug 9.
• [9] Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.Clin Lung Cancer. 2013 Nov;14(6):666-673.e2. doi: 10.1016/j.cllc.2013.04.010. Epub 2013 Jul 17.
• [10] Genome-wide association study of familial lung cancer.Carcinogenesis. 2018 Sep 21;39(9):1135-1140. doi: 10.1093/carcin/bgy080.
• [11] Next-Generation Cancer Immunotherapy Targeting Glypican-3.Front Oncol. 2019 Apr 10;9:248. doi: 10.3389/fonc.2019.00248. eCollection 2019.
• [12] Suppression of cleavage factor Im 25 promotes the proliferation of lung cancer cells through alternative polyadenylation.Biochem Biophys Res Commun. 2018 Sep 5;503(2):856-862. doi: 10.1016/j.bbrc.2018.06.087. Epub 2018 Jun 23.
• [13] Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer.Dis Markers. 2018 Dec 11;2018:9845123. doi: 10.1155/2018/9845123. eCollection 2018.
• [14] Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung.BMC Cancer. 2009 Jul 16;9:237. doi: 10.1186/1471-2407-9-237.
• [15] Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target.Cancer Sci. 2019 Aug;110(8):2607-2619. doi: 10.1111/cas.14108. Epub 2019 Jul 23.
• [16] Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.Mol Cancer. 2019 Jan 9;18(1):7. doi: 10.1186/s12943-019-0939-9.
• [17] Correlation of HPV-16/18 infection of human papillomavirus with lung squamous cell carcinomas in Western China.Oncol Rep. 2009 Jun;21(6):1627-32. doi: 10.3892/or_00000397.
• [18] NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma.Sci Rep. 2017 Dec 6;7(1):17064. doi: 10.1038/s41598-017-17298-x.
• [19] Expression of selected miRNA, RAR and FHIT genes in BALf of squamous cell lung cancer (squamous-cell carcinoma, SCC) patients: a pilot study.Mol Biol Rep. 2019 Dec;46(6):6593-6597. doi: 10.1007/s11033-019-05057-2. Epub 2019 Sep 9.
• [20] Prognostic Value of MAC30 Expression in Human Pure Squamous Cell Carcinomas of the Lung.Asian Pac J Cancer Prev. 2016;17(5):2705-10.
• [21] Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors.J Natl Compr Canc Netw. 2019 Apr 1;17(4):297-301. doi: 10.6004/jnccn.2019.7291.
• [22] m(6)A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression.Biochem Biophys Res Commun. 2018 Aug 25;502(4):456-464. doi: 10.1016/j.bbrc.2018.05.175. Epub 2018 Jun 2.
• [23] Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.Cancer Res. 2016 Sep 1;76(17):5103-14. doi: 10.1158/0008-5472.CAN-15-2980. Epub 2016 Apr 20.
• [24] Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
• [25] miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9.Cancer Lett. 2019 Apr 1;446:81-89. doi: 10.1016/j.canlet.2019.01.007. Epub 2019 Jan 17.
• [26] Systematic analysis identifies three-lncRNA signature as a potentially prognostic biomarker for lung squamous cell carcinoma using bioinformatics strategy.Transl Lung Cancer Res. 2019 Oct;8(5):614-635. doi: 10.21037/tlcr.2019.09.13.
• [27] Mining and validating the expression pattern and prognostic value of acetylcholine receptors in non-small cell lung cancer.Medicine (Baltimore). 2019 May;98(20):e15555. doi: 10.1097/MD.0000000000015555.
• [28] Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung.Clin Cancer Res. 2004 Sep 1;10(17):5792-803. doi: 10.1158/1078-0432.CCR-03-0317.
• [29] Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men.Cancer Biomark. 2010-2011;8(6):351-9. doi: 10.3233/CBM-2011-0224.
• [30] Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma.J Biochem. 2018 Dec 1;164(6):471-481. doi: 10.1093/jb/mvy074.
• [31] Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.Chest. 2014 Mar 1;145(3):473-479. doi: 10.1378/chest.12-2679.
• [32] EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.Oncogenesis. 2019 Sep 4;8(9):49. doi: 10.1038/s41389-019-0159-6.
• [33] FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma.Int J Oncol. 2015 Mar;46(3):999-1006. doi: 10.3892/ijo.2015.2817. Epub 2015 Jan 7.
• [34] LUBAC determines chemotherapy resistance in squamous cell lung cancer.J Exp Med. 2019 Feb 4;216(2):450-465. doi: 10.1084/jem.20180742. Epub 2019 Jan 14.
• [35] FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas.Thorac Cancer. 2017 Nov;8(6):655-665. doi: 10.1111/1759-7714.12504. Epub 2017 Sep 14.
• [36] Molecular profiling of genes in squamous cell lung carcinoma in Asian Indians.Life Sci. 2008 Mar 26;82(13-14):772-9. doi: 10.1016/j.lfs.2008.01.009. Epub 2008 Jan 30.
• [37] GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung.Dis Markers. 2008;24(1):41-50. doi: 10.1155/2008/857474.
• [38] Genomic sequencing and editing revealed the GRM8 signaling pathway as potential therapeutic targets of squamous cell lung cancer.Cancer Lett. 2019 Feb 1;442:53-67. doi: 10.1016/j.canlet.2018.10.035. Epub 2018 Oct 27.
• [39] Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.J Immunol. 2001 Feb 15;166(4):2871-7. doi: 10.4049/jimmunol.166.4.2871.
• [40] BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma.Nat Commun. 2018 Aug 20;9(1):3327. doi: 10.1038/s41467-018-05790-5.
• [41] Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma.Int J Oncol. 2016 Feb;48(2):450-60. doi: 10.3892/ijo.2015.3289. Epub 2015 Dec 14.
• [42] 9q33.3, a stress-related chromosome region, contributes to reducing lung squamous cell carcinoma risk.J Thorac Oncol. 2014 Jul;9(7):1041-1047. doi: 10.1097/JTO.0000000000000195.
• [43] Increased NM23: MTS1 ratio inversely correlated with metastasis behaviour in human lung squamous cell carcinoma.Anticancer Res. 1997 Jan-Feb;17(1A):407-11.
• [44] Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC.J Thorac Oncol. 2019 Feb;14(2):223-236. doi: 10.1016/j.jtho.2018.10.162. Epub 2018 Nov 5.
• [45] A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.Ann Surg Oncol. 2019 Jun;26(6):1925-1933. doi: 10.1245/s10434-019-07257-3. Epub 2019 Feb 27.
• [46] The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.Biosci Rep. 2017 Aug 31;37(4):BSR20170852. doi: 10.1042/BSR20170852. Epub 2017 Jul 19.
• [47] PKC regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.Oncogene. 2017 Jan 26;36(4):534-545. doi: 10.1038/onc.2016.224. Epub 2016 Jun 20.
• [48] The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma.Exp Mol Pathol. 2013 Dec;95(3):270-5. doi: 10.1016/j.yexmp.2013.07.008. Epub 2013 Jul 29.
• [49] Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.J Thorac Oncol. 2017 Jun;12(6):943-953. doi: 10.1016/j.jtho.2017.03.010. Epub 2017 Mar 21.
• [50] Genome-wide analysis of DNA methylation and the gene expression change in lung cancer.J Thorac Oncol. 2012 Jan;7(1):20-33. doi: 10.1097/JTO.0b013e3182307f62.
• [51] CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification.Cell Oncol (Dordr). 2019 Aug;42(4):449-458. doi: 10.1007/s13402-019-00434-2. Epub 2019 Mar 5.
• [52] Squalene epoxidase promotes the proliferation and metastasis of lung squamous cell carcinoma cells though extracellular signal-regulated kinase signaling.Thorac Cancer. 2019 Mar;10(3):428-436. doi: 10.1111/1759-7714.12944. Epub 2019 Feb 7.
• [53] Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.PLoS One. 2012;7(10):e46539. doi: 10.1371/journal.pone.0046539. Epub 2012 Oct 10.
• [54] Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.J Clin Oncol. 2014 Jan 10;32(2):121-8. doi: 10.1200/JCO.2013.50.8556. Epub 2013 Dec 9.
• [55] TBL1XR1 as a potential therapeutic target that promotes epithelial-mesenchymal transition in lung squamous cell carcinoma.Exp Ther Med. 2019 Jan;17(1):91-98. doi: 10.3892/etm.2018.6955. Epub 2018 Nov 12.
• [56] Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.Life Sci. 2018 Feb 1;194:1-6. doi: 10.1016/j.lfs.2017.12.020. Epub 2017 Dec 14.
• [57] MicroRNAs associated with lung squamous cell carcinoma: New prognostic biomarkers and therapeutic targets.J Cell Biochem. 2019 Nov;120(11):18956-18966. doi: 10.1002/jcb.29216. Epub 2019 Jun 26.
• [58] TPX2 in malignantly transformed human bronchial epithelial cells by anti-benzo[a]pyrene-7,8-diol-9,10-epoxide.Toxicology. 2008 Oct 30;252(1-3):49-55. doi: 10.1016/j.tox.2008.07.059. Epub 2008 Aug 3.
• [59] LSCC SNP variant regulates SOX2 modulation of VDAC3.Oncotarget. 2018 Apr 27;9(32):22340-22352. doi: 10.18632/oncotarget.24918. eCollection 2018 Apr 27.
• [60] TRIM58/cg26157385 methylation is associated with eight prognostic genes in lung squamous cell carcinoma.Oncol Rep. 2018 Jul;40(1):206-216. doi: 10.3892/or.2018.6426. Epub 2018 May 8.
• [61] STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.Clin Cancer Res. 2017 Jul 1;23(13):3442-3452. doi: 10.1158/1078-0432.CCR-16-1815. Epub 2017 Jan 13.
• [62] Expression analysis of genes at 3q26-q27 involved in frequent amplification in squamous cell lung carcinoma.Eur J Cancer. 1999 Apr;35(4):641-6. doi: 10.1016/s0959-8049(98)00419-5.
• [63] Synergistic association of CYP1A1 polymorphisms with increased susceptibility to squamous cell lung cancer in north Indian smokers.Int J Biol Markers. 2016 Dec 23;31(4):e402-e412. doi: 10.5301/jbm.5000221.
• [64] Genome-wide DNA methylation profiling reveals novel epigenetic signatures in squamous cell lung cancer.BMC Genomics. 2017 Nov 23;18(1):901. doi: 10.1186/s12864-017-4223-3.
• [65] Diagnostic value of serum dihydrodiol dehydrogenase 2 levels in patients with non-small-cell lung cancer.Int J Biol Markers. 2018 Jun 1:1724600818776832. doi: 10.1177/1724600818776832. Online ahead of print.
• [66] Deregulation of small non-coding RNAs at the DLK1-DIO3 imprinted locus predicts lung cancer patient outcome.Oncotarget. 2016 Dec 6;7(49):80957-80966. doi: 10.18632/oncotarget.13133.
• [67] Identification of key genes and long noncoding RNAs in celecoxibtreated lung squamous cell carcinoma cell line by RNAsequencing.Mol Med Rep. 2018 May;17(5):6456-6464. doi: 10.3892/mmr.2018.8656. Epub 2018 Mar 1.
• [68] Multiple mutations of lung squamous cell carcinoma shared common mechanisms.Oncotarget. 2016 Nov 29;7(48):79629-79636. doi: 10.18632/oncotarget.13190.
• [69] GAB2 Amplification in Squamous Cell Lung Cancer of Non-Smokers.J Korean Med Sci. 2017 Nov;32(11):1784-1791. doi: 10.3346/jkms.2017.32.11.1784.
• [70] A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.PLoS One. 2011;6(7):e22509. doi: 10.1371/journal.pone.0022509. Epub 2011 Jul 25.
• [71] High levels of nm23-H1 and nm23-H2 messenger RNA in human squamous-cell lung carcinoma are associated with poor differentiation and advanced tumor stages.Int J Cancer. 1993 Sep 30;55(3):375-9. doi: 10.1002/ijc.2910550306.
• [72] Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.Oncotarget. 2017 Mar 21;8(12):18885-18900. doi: 10.18632/oncotarget.13806.
• [73] Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.Int J Oncol. 2017 Aug;51(2):489-497. doi: 10.3892/ijo.2017.4055. Epub 2017 Jun 23.
• [74] Cross-cancer profiling of molecular alterations within the human autophagy interaction network.Autophagy. 2015;11(9):1668-87. doi: 10.1080/15548627.2015.1067362.
• [75] FAM163A, a positive regulator of ERK signaling pathway, interacts with 14-3-3 and promotes cell proliferation in squamous cell lung carcinoma.Onco Targets Ther. 2019 Aug 13;12:6393-6406. doi: 10.2147/OTT.S214731. eCollection 2019.
• [76] Landscape of transcriptional deregulation in lung cancer.BMC Genomics. 2018 Jun 5;19(1):435. doi: 10.1186/s12864-018-4828-1.
• [77] SFTA1P, LINC00968, GATA6-AS1, TBX5-AS1, and FEZF1-AS1 are crucial long non-coding RNAs associated with the prognosis of lung squamous cell carcinoma.Oncol Lett. 2019 Oct;18(4):3985-3993. doi: 10.3892/ol.2019.10744. Epub 2019 Aug 14.
• [78] HOPX is methylated and exerts tumour-suppressive function through Ras-induced senescence in human lung cancer.J Pathol. 2015 Feb;235(3):397-407. doi: 10.1002/path.4469. Epub 2014 Dec 18.
• [79] MEOX1 Promotes Tumor Progression and Predicts Poor Prognosis in Human Non-Small-Cell Lung Cancer.Int J Med Sci. 2019 Jan 1;16(1):68-74. doi: 10.7150/ijms.27595. eCollection 2019.
• [80] The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer.PLoS One. 2015 Nov 18;10(11):e0143376. doi: 10.1371/journal.pone.0143376. eCollection 2015.
• [81] Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung.Int J Cancer. 2007 Jun 15;120(12):2538-44. doi: 10.1002/ijc.22585.
• [82] Aquaporins 1, 3 and 5 in Different Tumors, their Expression, Prognosis Value and Role as New Therapeutic Targets.Pathol Oncol Res. 2020 Apr;26(2):615-625. doi: 10.1007/s12253-019-00646-9. Epub 2019 Mar 29.
• [83] Epigenetic upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes tumorigenesis of lung squamous cell carcinoma.Oncotarget. 2016 Dec 6;7(49):81571-81587. doi: 10.18632/oncotarget.13147.
• [84] Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma.J Hum Genet. 2012 Jan;57(1):38-45. doi: 10.1038/jhg.2011.126. Epub 2011 Nov 17.
• [85] FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.Clin Cancer Res. 2014 Aug 1;20(15):4107-14. doi: 10.1158/1078-0432.CCR-14-0284. Epub 2014 May 21.
• [86] Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.
• [87] Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.PLoS Med. 2010 Jul 27;7(7):e1000315. doi: 10.1371/journal.pmed.1000315.
• [88] Metastatic potential of lung squamous cell carcinoma associated with HSPC300 through its interaction with WAVE2.Lung Cancer. 2009 Sep;65(3):299-305. doi: 10.1016/j.lungcan.2009.06.001. Epub 2009 Jul 2.
• [89] High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.Thorac Cancer. 2018 Jul;9(7):775-784. doi: 10.1111/1759-7714.12643. Epub 2018 May 2.
• [90] Co-Expression Network Analysis Identified Genes Associated with Cancer Stem Cell Characteristics in Lung Squamous Cell Carcinoma.Cancer Invest. 2020 Jan;38(1):13-22. doi: 10.1080/07357907.2019.1697281. Epub 2019 Dec 6.
• [91] CD109 expression is upregulated in penile squamous cell carcinoma.Oncol Lett. 2017 Nov;14(5):6012-6016. doi: 10.3892/ol.2017.6975. Epub 2017 Sep 15.
• [92] CHFR expression is preferentially impaired in smoking-related squamous cell carcinoma of the lung, and the diminished expression significantly harms outcomes.Int J Cancer. 2008 Oct 1;123(7):1623-30. doi: 10.1002/ijc.23673.
• [93] Differential expression of CHL1 gene during development of major human cancers.PLoS One. 2011 Mar 7;6(3):e15612. doi: 10.1371/journal.pone.0015612.
• [94] CDKN1A-interacting zinc finger protein 1 is a novel biomarker for lung squamous cell carcinoma.Oncol Lett. 2018 Jan;15(1):183-188. doi: 10.3892/ol.2017.7282. Epub 2017 Oct 26.
• [95] Chrysin enhances anticancer drug-induced toxicity mediated by the reduction of claudin-1 and 11 expression in a spheroid culture model of lung squamous cell carcinoma cells.Sci Rep. 2019 Sep 24;9(1):13753. doi: 10.1038/s41598-019-50276-z.
• [96] Increased expression of claudin-12 promotes the metastatic phenotype of human bronchial epithelial cells and is associated with poor prognosis in lung squamous cell carcinoma.Exp Ther Med. 2019 Jan;17(1):165-174. doi: 10.3892/etm.2018.6964. Epub 2018 Nov 13.
• [97] Claudin-3 Inhibits Lung Squamous Cell Carcinoma Cell Epithelial-mesenchymal Transition and Invasion via Suppression of the Wnt/-catenin Signaling Pathway.Int J Med Sci. 2018 Feb 5;15(4):339-351. doi: 10.7150/ijms.22927. eCollection 2018.
• [98] Claudin-5, -7, and -18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma.Biochim Biophys Acta Mol Cell Res. 2017 Feb;1864(2):293-302. doi: 10.1016/j.bbamcr.2016.11.018. Epub 2016 Nov 21.
• [99] Aberrant expression of a hemidesmosomal protein, bullous pemphigoid antigen 2, in human squamous cell carcinoma.Lab Invest. 1996 Oct;75(4):589-600.
• [100] CORO1C expression is associated with poor survival rates in gastric cancer and promotes metastasis invitro.FEBS Open Bio. 2019 Jun;9(6):1097-1108. doi: 10.1002/2211-5463.12639. Epub 2019 Apr 29.
• [101] Mechanism of lung adenocarcinoma spine metastasis induced by CXCL17.Cell Oncol (Dordr). 2020 Apr;43(2):311-320. doi: 10.1007/s13402-019-00491-7. Epub 2019 Dec 12.
• [102] Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D.Lung Cancer. 2013 Feb;79(2):104-10. doi: 10.1016/j.lungcan.2012.10.012. Epub 2012 Nov 20.
• [103] Frequent silence of chromosome 9p, homozygous DOCK8, DMRT1 and DMRT3 deletion at 9p24.3 in squamous cell carcinoma of the lung.Int J Oncol. 2010 Aug;37(2):327-35.
• [104] Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma.Cell Res. 2016 Oct;26(10):1149-1164. doi: 10.1038/cr.2016.111. Epub 2016 Sep 27.
• [105] The p53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/ERK pathway in human lung cancer.Carcinogenesis. 2012 Dec;33(12):2326-33. doi: 10.1093/carcin/bgs273. Epub 2012 Aug 31.
• [106] Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese.J Cancer Res Ther. 2018;14(Supplement):S72-S78. doi: 10.4103/0973-1482.172108.
• [107] High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.PLoS One. 2017 Oct 31;12(10):e0187356. doi: 10.1371/journal.pone.0187356. eCollection 2017.
• [108] Elevated eukaryotic elongation factor 2 expression is involved in proliferation and invasion of lung squamous cell carcinoma.Oncotarget. 2016 Sep 6;7(36):58470-58482. doi: 10.18632/oncotarget.11298.
• [109] Five genes may predict metastasis in non-small cell lung cancer using bioinformatics analysis.Oncol Lett. 2019 Aug;18(2):1723-1732. doi: 10.3892/ol.2019.10498. Epub 2019 Jun 19.
• [110] Identification of lncRNAs associated with lung squamous cell carcinoma prognosis in the competitive endogenous RNA network.PeerJ. 2019 Sep 17;7:e7727. doi: 10.7717/peerj.7727. eCollection 2019.
• [111] ETV4 overexpression promotes progression of non-small cell lung cancer by upregulating PXN and MMP1 transcriptionally.Mol Carcinog. 2020 Jan;59(1):73-86. doi: 10.1002/mc.23130. Epub 2019 Oct 31.
• [112] Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma.J Cancer Res Clin Oncol. 2018 Aug;144(8):1509-1521. doi: 10.1007/s00432-018-2653-1. Epub 2018 May 4.
• [113] Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors.Sci Rep. 2017 Apr 4;7(1):641. doi: 10.1038/s41598-017-00219-3.
• [114] The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers.Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3469-74. doi: 10.1073/pnas.1421975112. Epub 2015 Mar 2.
• [115] Minimal deletion regions in lung squamous cell carcinoma: association with abnormality of the DNA double-strand break repair genes and their applications on gene identification and prognostic biomarkers.Lung Cancer. 2008 Mar;59(3):332-9. doi: 10.1016/j.lungcan.2007.08.038. Epub 2007 Nov 1.
• [116] Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.Cancer Control. 2018 Jan-Mar;25(1):1073274818778001. doi: 10.1177/1073274818778001.
• [117] Gephyrin suppresses lung squamous cell carcinoma development by reducing mTOR pathway activation.Cancer Manag Res. 2019 Jun 7;11:5333-5341. doi: 10.2147/CMAR.S204358. eCollection 2019.
• [118] Predicting the Lung Squamous Cell Carcinoma Diagnosis and Prognosis Markers by Unique DNA Methylation and Gene Expression Profiles.J Comput Biol. 2020 Jul;27(7):1041-1054. doi: 10.1089/cmb.2019.0138. Epub 2019 Nov 11.
• [119] Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population.Cancer Res. 1993 Jul 1;53(13):2994-9.
• [120] Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2305-11. eCollection 2014.
• [121] Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).BMC Cancer. 2018 Apr 16;18(1):429. doi: 10.1186/s12885-018-4215-y.
• [122] Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma.Oncotarget. 2017 Oct 27;8(57):97476-97489. doi: 10.18632/oncotarget.22138. eCollection 2017 Nov 14.
• [123] Analysis of HYAL3 gene mutations in Chinese lung squamous cell carcinoma patients.Tumori. 2013 Jan-Feb;99(1):108-12. doi: 10.1177/030089161309900118.
• [124] Decreased IFIT2 Expression In Human Non-Small-Cell Lung Cancer Tissues Is Associated With Cancer Progression And Poor Survival Of The Patients.Onco Targets Ther. 2019 Oct 3;12:8139-8149. doi: 10.2147/OTT.S220698. eCollection 2019.
• [125] WIF-1 and Ihh Expression and Clinical Significance in Patients With Lung Squamous Cell Carcinoma and Adenocarcinoma.Appl Immunohistochem Mol Morphol. 2018 Aug;26(7):454-461. doi: 10.1097/PAI.0000000000000449.
• [126] Comprehensive genomic and prognostic analysis of the IL?7 family genes in lung cancer.Mol Med Rep. 2019 Jun;19(6):4906-4918. doi: 10.3892/mmr.2019.10164. Epub 2019 Apr 15.
• [127] Prognostic value of aberrantly expressed methylation gene profiles in lung squamous cell carcinoma: A study based on The Cancer Genome Atlas.J Cell Physiol. 2019 May;234(5):6519-6528. doi: 10.1002/jcp.27389. Epub 2018 Sep 24.
• [128] IFN-gamma-induced change in microtubule organization and alpha-tubulin expression during growth inhibition of lung squamous carcinoma cells.J Interferon Cytokine Res. 2000 Nov;20(11):983-90. doi: 10.1089/10799900050198426.
• [129] High KRT8 Expression Independently Predicts Poor Prognosis for Lung Adenocarcinoma Patients.Genes (Basel). 2019 Jan 10;10(1):36. doi: 10.3390/genes10010036.
• [130] Human galectin-8 isoforms and cancer.Glycoconj J. 2002;19(7-9):557-63. doi: 10.1023/B:GLYC.0000014086.38343.98.
• [131] The Clinical Influence of Autophagy-Associated Proteins on Human Lung Cancer.Dis Markers. 2018 Jan 9;2018:8314963. doi: 10.1155/2018/8314963. eCollection 2018.
• [132] MCMs expression in lung cancer: implication of prognostic significance.J Cancer. 2017 Oct 9;8(18):3641-3647. doi: 10.7150/jca.20777. eCollection 2017.
• [133] Genomic variations in the counterpart normal controls of lung squamous cell carcinomas.Front Med. 2018 Jun;12(3):280-288. doi: 10.1007/s11684-017-0580-1. Epub 2017 Nov 28.
• [134] Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.Lancet Respir Med. 2019 Oct;7(10):881-891. doi: 10.1016/S2213-2600(19)30144-4. Epub 2019 Jul 17.
• [135] LSCDFS-MKL: A multiple kernel based method for lung squamous cell carcinomas disease-free survival prediction with pathological and genomic data.J Biomed Inform. 2019 Jun;94:103194. doi: 10.1016/j.jbi.2019.103194. Epub 2019 Apr 29.
• [136] Whole-exome sequencing to identify novel somatic mutations in squamous cell lung cancers.Int J Oncol. 2013 Sep;43(3):755-64. doi: 10.3892/ijo.2013.1991. Epub 2013 Jun 25.
• [137] Expression ratio of the TGF-inducible gene MYO10 is prognostic for overall survival of squamous cell lung cancer patients and predicts chemotherapy response.Sci Rep. 2018 Jun 22;8(1):9517. doi: 10.1038/s41598-018-27912-1.
• [138] Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information.Proteomics Clin Appl. 2019 Jan;13(1):e1800035. doi: 10.1002/prca.201800035. Epub 2018 Aug 21.
• [139] Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma.Cancer Sci. 2019 Jan;110(1):420-432. doi: 10.1111/cas.13853. Epub 2018 Dec 6.
• [140] Dissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinoma.Oncol Lett. 2018 Sep;16(3):3992-4000. doi: 10.3892/ol.2018.9113. Epub 2018 Jul 10.
• [141] NFIX downregulation independently predicts poor prognosis in lung adenocarcinoma, but not in squamous cell carcinoma.Future Oncol. 2018 Dec;14(30):3135-3144. doi: 10.2217/fon-2018-0164. Epub 2018 Nov 12.
• [142] A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma.Int J Cancer. 2006 Apr 15;118(8):1992-7. doi: 10.1002/ijc.21594.
• [143] Poly(A)-specific ribonuclease and Nocturnin in squamous cell lung cancer: prognostic value and impact on gene expression.Mol Cancer. 2015 Nov 5;14:187. doi: 10.1186/s12943-015-0457-3.
• [144] Gene amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in squamous cell lung carcinoma.Int J Oncol. 2000 Jul;17(1):67-73. doi: 10.3892/ijo.17.1.67.
• [145] PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway.EBioMedicine. 2019 Apr;42:311-325. doi: 10.1016/j.ebiom.2019.03.045. Epub 2019 Mar 25.
• [146] Podoplanin expression in cancer-associated fibroblasts predicts unfavourable prognosis in patients with pathological stage IA lung adenocarcinoma.Histopathology. 2018 Feb;72(3):490-499. doi: 10.1111/his.13390. Epub 2017 Nov 27.
• [147] PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.Cancer Med. 2015 Mar;4(3):325-32. doi: 10.1002/cam4.372. Epub 2015 Jan 9.
• [148] Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.Oncotarget. 2016 Dec 20;7(51):85063-85078. doi: 10.18632/oncotarget.13195.
• [149] A piRNA-like Small RNA Induces Chemoresistance to Cisplatin-Based Therapy by Inhibiting Apoptosis in Lung Squamous Cell Carcinoma.Mol Ther Nucleic Acids. 2017 Mar 17;6:269-278. doi: 10.1016/j.omtn.2017.01.003. Epub 2017 Jan 24.
• [150] Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer.Oncogene. 2020 Aug;39(32):5479-5493. doi: 10.1038/s41388-019-1129-3. Epub 2019 Dec 10.
• [151] Chromosomal localization of phospholipase A2 activating protein, an Ets2 target gene, to 9p21.Genomics. 1999 Dec 15;62(3):529-32. doi: 10.1006/geno.1999.5999.
• [152] Phospholipid Phosphatase 4 promotes proliferation and tumorigenesis, and activates Ca(2+)-permeable Cationic Channel in lung carcinoma cells.Mol Cancer. 2017 Aug 29;16(1):147. doi: 10.1186/s12943-017-0717-5.
• [153] Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma.Cancer Res. 2019 Dec 15;79(24):6084-6100. doi: 10.1158/0008-5472.CAN-19-2132. Epub 2019 Sep 24.
• [154] Protein regulator of cytokinesis-1 expression: prognostic value in lung squamous cell carcinoma patients.J Thorac Dis. 2017 Jul;9(7):2054-2060. doi: 10.21037/jtd.2017.06.91.
• [155] Promoter methylation-mediated downregulation of PRDM5 contributes to the development of lung squamous cell carcinoma.Tumour Biol. 2014 May;35(5):4509-16. doi: 10.1007/s13277-013-1593-2. Epub 2014 Jan 7.
• [156] The calcium-sensing receptor is necessary for the rapid development of hypercalcemia in human lung squamous cell carcinoma.Neoplasia. 2011 May;13(5):428-38. doi: 10.1593/neo.101620.
• [157] The 12p13.33/RAD52 locus and genetic susceptibility to squamous cell cancers of upper aerodigestive tract.PLoS One. 2015 Mar 20;10(3):e0117639. doi: 10.1371/journal.pone.0117639. eCollection 2015.
• [158] Screening and identification of key biomarkers in lung squamous cell carcinoma by bioinformatics analysis.Oncol Lett. 2019 Nov;18(5):5185-5196. doi: 10.3892/ol.2019.10873. Epub 2019 Sep 16.
• [159] MiR-92a Family: A Novel Diagnostic Biomarker and Potential Therapeutic Target in Human Cancers.Front Mol Biosci. 2019 Oct 1;6:98. doi: 10.3389/fmolb.2019.00098. eCollection 2019.
• [160] Expression of Mina53, a novel c-Myc target gene, is a favorable prognostic marker in early stage lung cancer.Lung Cancer. 2010 Aug;69(2):232-8. doi: 10.1016/j.lungcan.2009.10.010. Epub 2009 Nov 14.
• [161] Identification of reference genes for qRT-PCR in human lung squamous-cell carcinoma by RNA-Seq.Acta Biochim Biophys Sin (Shanghai). 2014 Apr;46(4):330-7. doi: 10.1093/abbs/gmt153. Epub 2014 Jan 23.
• [162] Surfactant protein B gene variations enhance susceptibility to squamous cell carcinoma of the lung in German patients.Br J Cancer. 2002 Jul 15;87(2):212-7. doi: 10.1038/sj.bjc.6600353.
• [163] Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma.PLoS One. 2012;7(2):e30398. doi: 10.1371/journal.pone.0030398. Epub 2012 Feb 17.
• [164] MicroRNAs modulate the expression of the SOX18 transcript in lung squamous cell carcinoma.Oncol Rep. 2016 Nov;36(5):2884-2892. doi: 10.3892/or.2016.5102. Epub 2016 Sep 19.
• [165] SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival.Biomed Pharmacother. 2018 Apr;100:233-239. doi: 10.1016/j.biopha.2018.02.015. Epub 2018 Feb 16.
• [166] T-cell intracellular antigens function as tumor suppressor genes.Cell Death Dis. 2015 Mar 5;6(3):e1669. doi: 10.1038/cddis.2015.43.
• [167] Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.PLoS One. 2017 Mar 29;12(3):e0174515. doi: 10.1371/journal.pone.0174515. eCollection 2017.
• [168] Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma.Int J Oncol. 2016 Nov;49(5):1870-1880. doi: 10.3892/ijo.2016.3690. Epub 2016 Sep 13.
• [169] Tripartite motif-containing 15 overexpression in non-small cell lung cancer is associated with poor patient prognoses.J Cancer. 2019 Jan 29;10(4):843-852. doi: 10.7150/jca.27856. eCollection 2019.
• [170] Novel methylation-driven genes identified as prognostic indicators for lung squamous cell carcinoma.Am J Transl Res. 2019 Apr 15;11(4):1997-2012. eCollection 2019.
• [171] Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma.J Cancer Res Clin Oncol. 2019 Apr;145(4):1027-1035. doi: 10.1007/s00432-019-02861-y. Epub 2019 Feb 27.
• [172] Overexpression of APC11 predicts worse survival in lung adenocarcinoma.Onco Targets Ther. 2018 Oct 17;11:7125-7132. doi: 10.2147/OTT.S177252. eCollection 2018.
• [173] Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.Neoplasia. 2009 Aug;11(8):763-70. doi: 10.1593/neo.09470.
• [174] YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation.Cancer Res. 2017 Nov 1;77(21):5769-5781. doi: 10.1158/0008-5472.CAN-17-0449. Epub 2017 Sep 15.
• [175] The association between RAD18 Arg302Gln polymorphism and the risk of human non-small-cell lung cancer.J Cancer Res Clin Oncol. 2008 Feb;134(2):211-7. doi: 10.1007/s00432-007-0272-3. Epub 2007 Jul 12.